Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Twinlab chapter 11 motions

This article was originally published in The Tan Sheet

Executive Summary

Approval of "first-day motions" by the U.S. Bankruptcy Court for southern N.Y. will allow Twinlab to "preserve its normal business operations...to the maximum extent possible," company announces Sept. 10. Court also approves motion for Twinlab to access up to $8.8 mil. of a $35 mil. debtor-in-possession facility financed by CIT Group. Funds will assist company in covering costs of operations during chapter 11 process. Twinlab announced plans to file for chapter 11 and sell its assets to IdeaSphere Sept. 4 (1"The Tan Sheet" Sept. 8, 2003, p. 14)...

You may also be interested in...



Twinlab Sells Assets To IdeaSphere, Files For Protection From Creditors

IdeaSphere will acquire all assets of dietary supplement manufacturer Twinlab for $65 mil. following the company's filing for Chapter 11 bankruptcy

OTC Sales Of Hearing Aids In US For Mild To Moderate Loss Allowed Under FDA Final Rule

After requirement from Congress and push from President Biden, FDA establishes regulatory category for hearing aids to allow US consumers with mild to moderate hearing loss to purchase the devices without a prescription or prior exam.

Safe Use Of Hydrogen-Peroxide Contact Lens Solution Magnified in US FDA Draft Guidance

Draft guidance pulls from Ophthalmic Devices Panel and Risk Communication Advisory Committee 2017 meeting to discuss more clearly communicating risks of the solutions to consumers while allowing products to remain available OTC.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS095941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel